News & Alerts
-
Oct- 2023 -6 October
Probiotics Market Surges as Gut Health Takes Center Stage in Global Wellness
The Probiotics Market stands at the forefront of nutritional innovation, offering progressive solutions within the burgeoning global health and wellness…
Read More » -
6 October
Federal Judge Approves Class Action for North Carolinians Affected by Toxic Water Pollution
In a significant legal development, U.S. District Judge James Dever in Raleigh has granted approval for more than 100,000 residents…
Read More » -
6 October
WHO Warns of Dengue Fever Surge in Southern United States, Europe, and Africa Due to Climate Change
Dengue fever, a tropical disease transmitted by Aedes aegypti mosquitoes, is poised to become a significant threat in regions where…
Read More » -
5 October
UniQure to Implement 20% Workforce Reduction in Major Restructuring Move
Dutch gene therapy company uniQure N.V. has announced a significant restructuring plan aimed at cost-saving measures. As part of this…
Read More » -
4 October
Roche’s Evrysdi Achieves Remarkable Milestone in SMA Treatment for Pre-Symptomatic Babies
In a groundbreaking development, Roche has unveiled highly positive results from the primary analysis of the ongoing RAINBOWFISH study, which…
Read More » -
4 October
AstraZeneca Settles Lawsuits Over Heartburn Drugs for $425 Million in Landmark Agreement
AstraZeneca, the British pharmaceutical giant, has reached a significant settlement in the United States to pay $425 million in order…
Read More » -
4 October
Boehringer Ingelheim Launches Highly Affordable Unbranded Humira Biosimilar
German pharmaceutical company Boehringer Ingelheim has made a major move in the biosimilar market by introducing an unbranded version of…
Read More » -
4 October
Kaiser Permanente Faces Labor Clash as Healthcare Workers Threaten Largest Strike in U.S. Medical Industry
Kaiser Permanente, a prominent healthcare network and managed-care organization, appeared to be on the brink of a significant labor conflict…
Read More » -
2 October
FDA Denies Approval for Eli Lilly’s Eczema Treatment Drug
The U.S. Food and Drug Administration (FDA) has made a decision not to approve Eli Lilly’s drug, which was intended…
Read More » -
2 October
Viatris Announces Strategic Divestitures Totaling $3.6 Billion
On Sunday, pharmaceutical company Viatris announced that it has reached agreements to divest several of its business segments, totaling up…
Read More »
